Gradually worsening dyspnea and dry cough in an elderly patient

Barisione, Emanuela; Rossi, Giovanni A.; Salio, Mario

doi:10.4081/monaldi.2017.834

Cited by 3 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endoscopic resection was significantly more common in the group developing residual or recurrent disease (75% vs. 9%, p = .001), likely due to incomplete surgical resection. All but two patients developing recurrence or progression of their disease had grossly residual disease after their definitive surgical intervention, 4,13,24,25,30,33 and the proportion of those with residual disease was significantly greater in this group compared to those not developing recurrence (75% vs. 4%, p < .001), highlighting the importance of obtaining adequate oncologic margins.…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Tracheal chondrosarcoma: A case report, systematic review, and pooled analysis

et al. 2021

View full text Add to dashboard Cite

Background: Tracheal chondrosarcoma is a rare malignancy, and formal treatment guidelines have not been established due to the lack of high quality studies. Best evidence at this time is limited to case reports.Aim: Explore the role of surgical intervention, radiation therapy, and chemotherapy, and the long-term outcomes for these interventions for tracheal chondrosarcoma.Methods and Results: A literature search was performed using PubMed and ResearchGate (1959-2020) using medical subject heading terms "tracheal chondrosarcoma" OR "trachea chondrosarcoma." Additional reports were identified within reviewed articles and included for review. Articles pertaining to chondrosarcomas of the lung, bronchus, larynx, or other head and neck subsites were excluded. Cases of chondromas were excluded. Thirty-five patients with tracheal chondrosarcoma were identified in the literature since 1959. Advanced age was significantly associated with recurrent or persistent disease (p = .003). The majority (77%) of cases were treated with open surgical resection, with an open approach and negative surgical margins being significantly associated with being disease-free after treatment (p = .001 and p < .001, respectively). Adjuvant radiotherapy was reserved for those unfit for surgery or for recurrent disease. Tumor size, extra-tracheal extension, tumor calcification, location, and initial diagnosis were not associated with tumor recurrence. Conclusion:Non-metastatic tracheal chondrosarcoma can be treated by adequate surgical resection, with little to no role for adjuvant radiotherapy or chemotherapy.Open surgery and negative margins were associated with oncologic control, while advanced age was associated with recurrent or persistent disease.

show abstract

Section: Discussionmentioning

confidence: 89%

“…Our literature search yielded 32 English language publications describing a total of 33 patient reports 3–33 and 5 non‐English language publications reports 34–38 describing a total of 5 patients. One case report lacked significant patient data and was excluded.…”

Section: Resultsmentioning

confidence: 99%

Tracheal chondrosarcoma: A case report, systematic review, and pooled analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Primary tumors of the trachea are a rare entity. Reports estimate an approximate incidence of 0.1% for every 100000 people [1][2][3][4] and an approximate prevalence of 2.6 cases per million people every year [5][6][7][8][9] . They account for only 0.1%-0.4% of all malignant neoplastic diseases [7][8][9][10][11][12][13][14][15][16] and represent about 2% of all airway malignancies [17][18][19][20] .…”

mentioning

confidence: 99%

A SEER database cohort of 868 patients with primary tracheal cancers: characteristics and outcomes and the role of bronchoscopic interventions

Baig¹,

Weber²,

Connery³

et al. 2020

International Journal of Surgery Oncology

View full text Add to dashboard Cite

Introduction: Primary tracheal cancers have a yearly prevalence of 2.6 cases per million people. Because of their rarity there is a lack of studies investigating them. In this study, we investigate the clinical characteristics and outcomes of primary tracheal cancers using a large population database. Methods: The Surveillance, Epidemiology and End Results (SEER) database was queried between 1973 and 2016 to identify a retrospective cohort of patients with primary tracheal cancers. Demographic information, tumor characteristics, treatments administered, and survival in months were investigated. Results: Eight hundred sixty-eight cases were analyzed. The majority of the patients were male (56.8%) with an average age of 62.13 ( ± 15.67). Squamous cell carcinoma (SCC) was the predominant subtype (42.9%) followed by adenoid cystic carcinoma (ACC) (18.1%). Five-year survival was 21.6% and median survival was 12 months. Patients with ACC had more localized tumors, received surgery more often and had longer survival than patients with SCC (P < 0.01). Both groups had best outcomes when treated with surgery. Bronchoscopic intervention was associated with favorable outcomes for ACC. For SCCs, bronchoscopic interventions followed by adjuvant therapy had better outcomes than radiotherapy alone. Cox proportional hazards identified advanced age and stage, radiotherapy and chemotherapy as negative predictors of outcome. Whereas ACC and sarcoma histology and diagnosis between 2010 and 2016 were positive prognosticators. Conclusions: Tracheal cancers have poor outcomes with a median survival of 12 months and 5-year survival of only 21.6%. Surgical resection should be the treatment of choice wherever feasible. In patients with ACCs who are not surgical candidates bronchoscopic interventions may provide appropriate treatment and palliation and improved survival. For SCCs, bronchoscopic intervention wherever possible with adjuvant therapy may be favorable to radiotherapy alone.

show abstract